Immunopathology Flashcards

1
Q

Disorders of the immune system:

What are the 4 major catergories?

A
  1. Immune system is functioning normally even thouggh something has gone wrong (TB)
  2. Immune system isn’t functioning properly (allergy/cancer)
  3. Immune system is incomplete (immunodeficiency)
  4. Immune system reacts to ‘self’ (autoimmunity)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Immune system functions normally: Give an example

A
  • Macrophages just doing their job but still can’t clear the pathogen that causes tuberculosis
  • Caused by infection with the TB bacterium (Mycobacterium tuberculosis)
  • Inhalation of bacteria via lungs (it is very small so can get into the alveoli of the lungs)
  • Alveolar macrophages are stationed here, ready to repel invaders
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the steps in phagocytosis?

A
  1. Macrophage detects bacterium
  2. Internalisation of bacterium in a phagosome
  3. Fusion of phagosome with lysosome creates the phagolysosome
  4. Degradative enzymes pumped into phagolysosome
  5. Excretion of digested bacterial particles
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How is phagocytosis disrupted in TB?

A
  1. Macrophage detects TB (mycobacterium)
  2. Internalisation of bacterium in a phagosome
  3. TB modifies phagosome surface - prevents fusion with lysosome
  4. Multiplication of TB in phagosome
  5. Macrophage dies; multiple TB organisms are released
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Explain how TB-infected macrophages die by necrosis

A

Macrophages full of miroplasma (bacteria) form a congregation of cells that are oxygen deprived (because they are so big) so become necrotic

  • Necrosis causes tissue damage
  • Necrosis initiates an inflammatory response
  • Recruitment of immune cells to site – more tissue damage
  • Cytokine release – hyperactivates macrophages
  • Better killing but increased risk
  • Granulomas form – macrophages full of bacteria
  • Alveloli taken up by ganulomas compromises gas exchange- lung function decreases
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

The immune system isn’t functioning properly: Give an example

A
  • Sometimes, the immune system responds to ‘safe’ as if it were dangerous
  • Allergies are an immune response to common environmental antigens (called allergens)
  • ⅓ of the UK population has an allergy
  • Non-allergic people respond weakly to allergens with low IgG production – no problem
  • Atopic (allergic) people respond with lots of IgE – allergic response
  • Allergic asthma is caused by an allergen but can be triggered by non-specific stimuli as well
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What do all alergens have in common?

A

Allergic reactions have two phases:

The early phase and the delayed phase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the difference between allergens and triggers?

A

Triggers make allergic symptoms worse even though they are not directly turning on your immune system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q
  1. Explain the early and late phases of an allergic response
A

Early phase:

  1. Antigen binds to the surface of mast cells
  2. Mast cells have IgE on their surface bound by their Fc (constant fragment)
  3. When the antigens crosslinks two IgE molecules the mast cell is full of granules
  4. The different granules e.g histamine, leukotrienes AND spasmogens confer allergen symptoms including bronchoconstriction

Delayed phase:

  1. Different cell types such as T cells (Th2), monocytes and eosinophils get involved
  2. Spasmogens are involed (LTC4 and LTD4)
  3. They cause another round of bronchoconstriction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Why make IgE and produce eosinophils if they are so bad for you?

A
  • It’s not all bad – these cell types and IgE/FceR are needed and have evolved for defence against parasitic worms
  • Release of granules from eosinophils breaks worms into ‘bite-size’ pieces for macrophages to eat
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

The immune response isn’t complete: Give examples

A
  • Primary immunodeficiency diseases- (PID) Diseases you are born with
  • Acquired immunodeficiency (HIV infection & AIDS)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Explain Primary immunodeficiency diseases (PID)

A
  • Inherited; many X-linked (>100 types)
  • General incidence 1:10,000 (considered rare diseases)
  • Mostly irreversible & dominate in infancy (poor survival)
  • Current treatments include:
  • Immunoglobulin supplementation→ An injection approx every 6 weeks (you need a lot of blood donors then those immunoglobulins need to be harvested)
  • Antibiotic therapy → leads to issues with antibiotic resistance
  • Bone marrow transplants (cure but very risky)
  • PID may affect innate or adaptive immunity
  • PID are categorised according to the immunological component(s) involved:
  • Lymphoid cell disorders may affect T cells, B cells or both
  • Myeloid cell disorders affect phagocytes
  • Defects early in haematopoiesis are most severe as they affect the entire immune system; usually fatal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Where does it all go wrong in PID?

A

Everywhere

The image shows the hierarchy of immune cells developing frim the haematopetic stem cell through either the myeloid or lymphoid progenitor down to the more specific and mature cell types

The further down, the less severe the disease but it also depends on what cell types are being affected

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Explain Acquired immunodeficiency (AIDS)

A
  • Infection with HIV initially causes an influenza-like illness, then a latent, asymptomatic phase.
  • For the most part HIV viruses are picked up by dendritic cells so they can be actively infected by HIV.
  • When the dendritic cell enters the lymph node, it allows the virus to also infect (CD4) T cells
  • Once the CD4 T cell is infected the virus will insert its genome into the cells DNA and take oer the cell to turn it into a HIV factory
  • When the CD4 lymphocyte count falls below 200 cells/ml of blood, the HIV host has progressed to AIDS
  • This is characterized by a deficiency in cell-mediated immunity
  • The result is increased susceptibility to opportunistic infections and certain forms of cancer.

Loss of CD4 T cells eventually means the loss of adaptive immunity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is Highly active antiretroviral therapy (HAART)?

A

The use of multiple antiretroviral drugs hitting multiple targets in an attempt to control HIV infection. Useful because the virus has few proofreading mechanism so is likely to become resistant to drugs.

  1. Reverse transcriptase inhibitors (first to be discovered- tested as a cancer drug before)→ Genomic RNA of the virus turns into DNA so cant make copies of itself
  2. Protease inhibitors→ HIV makes one long peptide from its genome and it needs a protease to chop it up to get the useful bits of protein that it needs to assemble itself- inhibiting the HIV protease prevents it from assembling new virus particles
  3. Ingegrase inhibitors → Keeps viral DNA away from human DNA (virus not able to intergrate itself therefore not able to hide in the cell for very long)
  4. Fusion/ entry inhibitors→ Blocks co-receptors like CCR5 so HIV cant get into the cell initially so will be delt with by the complement system
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Explain how the immune system reacts to ‘self’ (autoimmunity):

A
  • The immune system recogenises your own proteins as dangerous
  • The immune system doesn’t check every cell for self-reactivity (tolerance) – too expensive
  • Instead it’s developed as a multi-layered system with mechanisms to try and ‘weed out’ unwanted, self-reactive cells
  • This usually works but when it doesn’t, the body will react to itself
  • Autoimmune diseases are the result
  • Autoimmune diseases affect 3% of the population

(although they are quite rare, they are chronic, usually incurable, long-term and debilitating)

17
Q

What are the three requirements for autoimmunity?

A
  1. MHC presents self peptide (MHC is not strictly regulated)

Inheritable element

  1. TCR and/or BCR recognises self antigen

Completely random

  1. Breakdown of normal tolerance mechanisms (caused by danger signals initiated by trauma or viral infection for example, that alerts the immune system to attack your proteins)

More T helper cells than T regulatory cells (ratio changes)

You need the regulatory cells to calm down your immune system and stop things from getting out of hand

18
Q

What do mechanisms and symptoms of autoimmunity depend on?

A

The cell type(s) involved e.g. humoral (antobodies) or cell mediated (autoreactive T cells)

19
Q

Symptoms/severity will vary depending on the target organ/system: Give examples of organ-specific autoimmune diseasesand their major target

A
  • Graves’ disease →Thyroid
  • Hashimoto’s thyroiditis →Thyroid
  • IDDM →Pancreatic beta cells
  • (Type 1 diabetes mellitus, juvenile onset) →Pancreatic beta cells
  • Myasthenia gravis → Neuromuscular junction
20
Q

Symptoms/severity will vary depending on the target organ/system:

Give examples of Multi-system autoimmune diseases and their major target

A

Multiple sclerosis → Brain or white matter

Rheumatoid arthritis → Connective tissue

Systemic lupus erythematosus (SLE) → DNA, nuclear protein, RBC membrane

21
Q

Explain cancer immunology

A
  • Cancer can arise in immune cells
  • Leukaemia, lymphoma

or

  • Cancers that arise in other tissues (most tumours are derived from epithelial cells) have various mechanisms to evade destruction by the immune system
  • Immune editing allows tumours to lie dormant in patients for years
  • Tumours modify regulatory T cell function and antigen presentation, leading to tolerance and immune deviation
  • Tumour heterogeneity and metastasis play a role in tumour growth
22
Q

Explain tumour antigen expression

A

Tumours can express tumour antigens that are recognized by the immune system and may induce an immune response

Tumour-specific antigens (TSA) are antigens that only occur in tumour cells

  • products of oncoviruses like E6 and E7 proteins of human papillomavirus or EBNA-1 protein of Epstein-Barr virus
  • abnormal products of mutated oncogenes (e.g. Ras) and anti-oncogenes (e.g p53)

Tumour-associated antigens (TAA) are present in both healthy cells and tumour cells, but differ in quantity, location or time of expression

  • examples: oncofoetal antigens such as α-fetoprotein, carcinoembryonic antigen, HER2/neu, EGFR and MAGE-1
23
Q

How should the immune system attak cancer?

A
  1. Tumour cells release tumour antigens
  2. APCs gather tumo antigens and prepare tp present to naiive T cells
  3. T cells are activated by the APC
  4. Activated T cells find the tumour cells with the same tumor antigens and destroy them
24
Q

How can the immune response be suppressed?

How is TGF-β involved?

A
  • Decreased MHC expression
  • Co-stimulatory molecule expression
  • Infiltration of different types of immune cells e.g. macrophages and if they are alternatively activated they can produced a lot of mediators TGF-β which is an immunosuppressant (can suppress T cells and cause them to differentiate into regulatory cells instead of actively killing T cells
  • TGF-β can also induce epithelial to mesenchymal transition (EMT) in which the epithelial cells loose their conections to each other and become more migratory which leads to metastasis into bone, brain, lung etc
25
Q

Cancer immunotherapy-There are various cancer immunotherapy approaches to boost the response of the immune system to cancer cells:

A

Immunotherapy has shown significant potential as a more targeted approach to treating cancer by harnessing the body’s immune system to fight tumour cells

  • Adoptive T-cell therapy – consists of tuning the patient’s tumour-specific T cells to help boost the ability of their immune system to overwhelm the tumour
  • Immune checkpoint modulators – use monoclonal antibodies against specific receptors that modulate immune response. Cancer cells over-express these receptors to escape detection and destruction by the immune system.
  • Combination immunotherapy – combination of traditional therapies or combination of monoclonal antibody inhibitors with other checkpoint inhibitors or pathways, e.g. CTLA-4 blockade plus PD-1/PD-L1 blockade for a synergistic effect.
  • Vaccines – involves administration of neoantigens or other antigens that can be targeted by the T cells (e.g. targets for T cell recognition) to stimulate the patient’s immune responses against the tumour cells.
26
Q

What is cancer immunoediting?

What are the main stages of how the immune stages reacts to tumours?

A
  • Interactions between tumour cells and the immune system induces a process called cancer immunoediting, which consists of three phases: elimination, equilibrium and escape
  • Both the adaptive and innate immune system participate in immunoediting
  • In the elimination phase, the immune response leads to destruction of tumour cells and therefore to tumour suppression
  • However, some tumour cells may gain more mutations, change their characteristics and evade the immune system. These cells can enter the equilibrium phase, in which the immune system doesn’t recognise all tumour cells, but at the same time the tumour doesn’t grow. They do this by down-regulating MHC class I or up-regualting CTLA-4 or PDL1 that supresses T cells.
  • As a consequence of immunoediting, tumour cell clones less responsive to the immune system gain dominance in the tumour over time, as the recognized cells are eliminated. These surviving cells can escape the immune system.
27
Q

Describe Adoptive chimaeric antigen receptor (CAR) T cell therapy

A
  • Adoptive T cell therapy involves isolation of tumour-specific T cells from patients and their expansion ex vivo – provides a (hopefully) large number of tumour-specific T cells
  • These T cells are then engineered to express chimeric antigen receptors (CARs) that recognize cancer-specific antigens
28
Q

Explain CAR T Cell efficacy

What did the first approved treatment use?

What other blood cancer antigens has CARs been engineered to target?

Why has iddntification of good antigens been challenging?

A
  • Early CAR-T cell research focused on blood cancers
  • The first approved treatments uses CARs that target the antigen CD19, present in B-cell-derived cancers such as acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL).
  • There are also efforts underway to engineer CARs targeting many other blood cancer antigens, including CD30 in refractory Hodgkin’s lymphoma; CD33, CD123, and FLT3 in acute myeloid leukemia (AML); and BCMA in multiple myeloma
  • Solid tumours have presented a more difficult target
  • Identification of good antigens has been challenging: such antigens must be highly expressed on the majority of cancer cells, but largely absent on normal tissues.
  • CAR-T cells are also not trafficked efficiently into the centre of solid tumour masses, and the hostile tumour microenvironment suppresses T cell activity
29
Q

Explain the importance of Immune checkpoint modulators

A
  • Many checkpoints are present in the immune response to ensure that the cells of the immune system do not mistakenly destroy healthy cells during an immune response (autoimmune reaction)
  • Cancer cells have adapted to exploit these immune checkpoints as way to evade immune detection and elimination
  • By using checkpoint inhibitors (blocking PD-1, PD-L1 and CTLA-4 with monoclonal antibodies), the immune system can overcome the cancer’s ability to resist the immune responses and stimulate the body’s own mechanisms to remain effective in its defences against cancer
30
Q

What are the main classes of checkpoint inhibitors?

A
  • CTLA-4 blockade
  • PD-1 inhibitors
  • PD-L1 inhibitors
31
Q

Checkpoint inhibitors- CTLA-4 blockade

A
  • The first checkpoint antibody approved by the FDA was ipilimumab, approved in 2011 for treatment of melanoma
  • It blocks the immune checkpoint molecule CTLA-4
  • Clinical trials have also shown some benefits of anti-CTLA-4 therapy on lung cancer or pancreatic cancer, specifically in combination with other drugs
  • However, patients treated with CTLA-4 blocking antibodies are at high risk of suffering from immune-related adverse events such as dermatologic, gastrointestinal, endocrine, or hepatic autoimmune reactions
32
Q

What does it mean if drug ends in ‘mab’?

A

It belongs to the class of monoclonal antibodies (a humanised antibody against a specific target)

33
Q

Checkpoint inhibitors: PD-1 inhibitors

A
  • Initial clinical trial results with IgG4 PD-1 blocking antibody nivolumab (under the brand name Opdivo and developed by Bristol-Myers Squibb) were published in 2010 and it was approved in 2014
  • Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin’s lymphoma
  • Pembrolizumab (brand name Keytruda) is another PD1 inhibitor that was approved by the FDA in
34
Q

Checkpoint inhibitors- PD-L1 inhibitors

A

In May 2016, PD-L1 inhibitor atezolizumab was approved for treating bladder cancer

35
Q

Explain Combination immunotherapy

A
  • The efficiency of the immune checkpoint blockade with monoclonal antibodies in cancer treatment is remarkable and has durable effects; however, it is limited to a subset of patients
  • To enhance and broaden the anti-tumour activity of immune checkpoint inhibition, the next step is combining agents with synergistic mechanisms of action, e.g. PD-1/PD-L1 inhibition blockage with a complementary checkpoint inhibitor against CTLA-4
  • Another example is IDO (indoleamine-pyrrole 2,3-dioxygenase), an immunosuppressive enzyme expressed in the tumour microenvironment either by tumour cells or host immune cells
  • Combined IDO inhibition and immune checkpoint blockade is currently under clinical investigation, with promising initial results.
36
Q

Explain cancer vaccines:

What are they efficient for?

What do they consist of?

What do they target?

A
  • Vaccines may be particularly efficient for low mutational burden tumours, where anti-PD1 monotherapy efficiency is limited by low levels of T cell clones primed for tumour antigens
  • Cancer vaccines consists of the administration of tumour-associated antigens – for example melanoma-associated antigen-A3 (MAGE-A3) – in the form of either peptides or recombinant proteins in the presence of adequate adjuvants (an additional component that stimulates the immune response)
  • Targeting biologically relevant antigens via vaccination in animal models has resulted in both tumour inhibition and modulation of the biology of the tumour to make cancer more amenable to standard treatments
  • The vaccines are effectively reprogramming dendritic cells. They can be harvested, loaded with antigen and given another stimulant (adjuvant) that hyperactivates the dendritic cell which get sent back into the patients body.
  • The dendritic cells are already programmed to present antigen to T cells so they migrate to the lymph node and activate T cells which will seek out and destroy tumours.
37
Q

Give a summary of immunopathology

A

The immune system is set up to protect us; it can distinguish between self and non-self and reacts appropriately to a huge (unlimited?) variety of potential dangers

A system this powerful needs to be carefully regulated…

…and when it’s not the consequences are devastating:

  • Chronic TB infection (hijacked)
  • Allergies (dysfunction)
  • Immunodeficiency (no function)
  • Autoimmunity (inappropriate function)
  • Cancer (suppression)
38
Q

What are the main methods of cancer immunotherapy?

A